文献速递肝病

慢加急性肝衰竭患者的公平与正义:行动呼吁

'Equity' and 'Justice' for patients with acute-on chronic liver failure: A call to action.
PubMed 文献 · J Hepatol · 2021-06-23

慢加急性肝衰竭(ACLF)发生于住院肝硬化患者,以多器官衰竭和短期高死亡率为特征。未行肝移植时,ACLF 1级28天死亡率18-25%,3级达68-89%。现行分配政策基于低估死亡风险的预后评分,导致ACLF患者肝移植机会不均等。本文主张ACLF患者应依预后模型优先获得肝移植,并提出全球CHANCE研究设计及推广新分配政策。

要点

  • ACLF 1级未移植28天死亡率18-25%,3级达68-89%。
  • 现行分配政策低估ACLF死亡风险,导致移植机会不均等。
  • 呼吁基于预后模型优先分配肝移植,并推广新政策。

核心结论

  • ACLF患者因现行分配政策未获得公平的肝移植机会,应基于预后模型优先分配肝移植。

研究设计与样本

  • 专家意见类文章,基于现有证据论述并描述全球CHANCE研究设计。

主要发现

  • 未行肝移植的ACLF患者28天死亡率:1级18-25%,3级68-89%。
  • 现行分配政策基于低估ACLF死亡风险的预后评分,导致移植机会不均等。
  • 经仔细选择的ACLF患者肝移植后结局良好,但证据未被充分认识。

关键数值与推荐

  • ACLF 1级未移植28天死亡率18-25%,3级68-89%。

临床怎么用

  • 临床应基于预后模型评估ACLF患者死亡风险,优先分配肝移植。
  • 关注ACLF患者肝移植后不良结局的危险因素。
  • 推动全球采用新的器官分配政策,如英国已启动、西班牙推荐的政策。

局限性

  • 本文为专家意见,非系统研究,结论基于现有证据论述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute-on-chronic liver failure (ACLF) occurs in hospitalised patients with cirrhosis and is characterised by multiorgan failures and high rates of short-term mortality. Without liver transplantation (LT), the 28-day mortality rate of patients with ACLF ranges from 18-25% in those with ACLF grade 1 to 68-89% in those with ACLF grade 3. It has become clear that patients with ACLF do not have equitable access to LT because of current allocation policies, which are based on prognostic scores that underestimate their risk of death and a lack of appreciation of the clear evidence of transplant benefit in carefully selected patients (who can have excellent post-LT outcomes). In this expert opinion, we provide evidence supporting the argument that patients with ACLF should be given priority for LT based on prognostic models that define the risk of death for these patients. We also pinpoint risk factors for poor post-LT outcomes, identify unanswered questions and describe the design of a global study, the CHANCE study, which will provide answers to the outstanding issues. We also propose the worldwide adoption of new organ allocation policies for patients with ACLF, as have been initiated in the UK and recommended in Spain.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Jalan R, Gustot T, Fernandez J, et al. 'Equity' and 'Justice' for patients with acute-on chronic liver failure: A call to action. J Hepatol. 2021. PMID: 34171434. doi:10.1016/j.jhep.2021.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。